EGFR and neoplasm: Our data identified reduced tumor gene mutation frequency in the C1 group relative to the C2 group, including TP53 (32% in C1 vs. 34% in C2), EGFR (16% in C1 vs. 34% in C2), TTN (27% in C1 vs. 28% in C2) and MUC16 (14% in C1 vs. 17% in C2) (Figure 4A).